{
  "docId": "019de073-ace7-72fb-abe1-daa413db1006",
  "docSlug": "7bdf7da39a85a072a380631ad1d0379d",
  "documentTitle": "Cabaletta Bio | Investor Presentation Deck | 23 slides",
  "authorId": "cabaletta-bio",
  "authorName": "Cabaletta Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 23,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a numbered list format to structure the two primary pillars of their competitive advantage.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ace7-72fb-abe1-daa413db1006/12",
  "deckHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006",
  "deckJsonHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006.json",
  "deckAnchorHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.78
      },
      "kind": "callout",
      "text": "IND submission for CABA-201 anticipated in first half of 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d365e1cc-9fcc-4b81-92a9-ad8fc1615536",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Cabaletta is uniquely positioned to efficiently advance CABA-201 in autoimmune diseases. Expertise in conducting complex, interdisciplinary autoimmune-focused cell therapy clinical trials. Positive regulatory interactions. Successful manufacturing track record.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a5118fa-5f36-432e-8caa-da4b5addc071",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Clinically-evaluated binder & translational research partnership support CABA-201 development. CABA-201 leverages similar design to 4-1BB-containing CD19-CAR T in seminal academic SLE study. Exclusive research partnership.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff1e8e3a-134d-4e1f-87c6-3e736eba973a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Differentiated asset, exclusive translational insights & track record of timely CAART clinical implementation",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56160ef0-8018-41b0-bada-77c4ea7feb3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "SLE - Systemic lupus erythematosus. 1. Mackensen, Andreas, et al. \"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.\" Nature Medicine (2022): 1-9.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12e2a9c3-56b3-430a-ae44-b1acb8a84678",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Accelerating development of CABA-201 for autoimmune diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a52656d-bbc3-4d3d-9424-829eaebe6a28",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}